IMMUNE STUDIES IN HOMOSEXUAL MEN AT RISK FOR ACQUIRED IMMUNE DEFICIENCY SYNDROME

来自HTLV-III抗体（+）和（-）供体的外周血白细胞（PBL） 检测增殖性（3 H）和细胞介导的淋巴细胞溶解（CML）， 流感病毒（S+X）和HLA同种异体细胞（ALLO）。 抗体间 （+）供体，约50%未能对S+X作出反应，而所有 对ALLO有反应，但处于艾滋病关键阶段的患者除外， 对两种免疫原都没有反应 使用来自抗体（-）供体的PBL，我们通过细胞分级证明了 S+X T细胞应答必须使用CD 4 + T细胞的技术， 而ALLO应答可以由CD 4+或CD 4- T细胞产生。 因此，S+X反应的选择性丧失可能反映了 艾滋病发展过程中的CD 4+细胞。 利用上述方法，我们已经测试了艾滋病患者的T细胞功能 正在接受胸苷类似物AZT治疗 一些患者接受 AZT表现出T细胞免疫功能的恢复。 用HTLV-III刺激后感染来自抗体（-）供体的PBL PHA或HLA同种异体抗原。 PHA刺激细胞早期产生病毒 但培养物在2周内死亡。 相反，同种异体抗原刺激 培养物存活并产生病毒至少40天。

Peripheral blood leukocytes (PBL) from HTLV-III antibody (+) and (-) donors were tested for proliferative (3H) and cell-mediated lympholysis (CML) to influenza virus (S+X) and to HLA allogeneic cells (ALLO). Among antibody (+) donors, approximately 50% failed to respond to S+X, whereas all responded to ALLO, except patients in the critical stages of AIDS, who responded to neither type of immunogen. Using PBL from antibody (-) donors we demonstrated by cell fractionation techniques that S+X T cell responses are obliged to use CD4+ T cells, whereas ALLO responses can be generated by either CD4+ or CD4- T cells. Thus, the selective loss of S+X responses probably reflects the loss of CD4+ cells during AIDS development. Using the above approach, we have tested T cell functions in AIDS patients undergoing therapy with the thymidine analog AZT. Some patients undergoing AZT exhibited a restoration of T cell immune function. PBL from antibody (-) donors were infected with HTLV-III after stimulation with PHA or HLA alloantigens. PHA stimulated cells produced virus early but the cultures died within 2 weeks. In contrast, alloantigen stimulated cultures survived and produced virus for at least 40 days.